Literature DB >> 23152512

Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.

Thomas H R Carlsen1, Troels K H Scheel, Santseharay Ramirez, Steven K H Foung, Jens Bukh.   

Abstract

The hepatitis C virus (HCV) envelope proteins E1 and E2 play a key role in host cell entry and represent important targets for vaccine and drug development. Here, we characterized HCV recombinants with chimeric E1/E2 complexes in vitro. Using genotype 1a/2a JFH1-based recombinants expressing 1a core-NS2, we exchanged E2 with functional isolate sequences of genotypes 1a (alternative isolate), 1b, and 2a. While the 1a-E2 exchange did not impact virus viability, the 2a-E2 recombinant was nonviable. After E2 exchange from three 1b isolates, long delays were observed before spread of infection. For recovered 1b-E2 recombinants, single E2 stem region amino acid changes were identified at residues 706, 707, and 710. In reverse genetic studies, these mutations increased infectivity titers by ~100-fold, apparently without influencing particle stability or cell binding although introducing slight decrease in particle density. In addition, the 1b-E2 exchange led to a decrease in secreted core protein of 25 to 50%, which was further reduced by the E2 stem region mutations. These findings indicated that compensatory mutations permitted robust infectious virus production, without increasing assembly/release. Studies of E1/E2 heterodimerization showed no differences in intracellular E1/E2 interaction for chimeric constructs with or without E2 stem region mutations. Interestingly, the E2 stem region mutations allowed efficient entry, which was verified in 1a-E1/1b-E2 HCV pseudoparticle assays. A CD81 inhibition assay indicated that the mutations influenced a late step of the HCV entry pathway. Overall, this study identified specific amino acids in the E2 stem region of importance for HCV entry and for production of infectious virus particles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152512      PMCID: PMC3554168          DOI: 10.1128/JVI.00684-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry.

Authors:  Guillemette Maurin; Judith Fresquet; Ophélia Granio; Czeslaw Wychowski; François-Loïc Cosset; Dimitri Lavillette
Journal:  J Biol Chem       Date:  2011-05-09       Impact factor: 5.157

2.  In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.

Authors:  Akito Sakai; Shingo Takikawa; Robert Thimme; Jean-Christophe Meunier; Hans Christian Spangenberg; Sugantha Govindarajan; Patrizia Farci; Suzanne U Emerson; Francis V Chisari; Robert H Purcell; Jens Bukh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

3.  Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins.

Authors:  Heidi E Drummer; Anne Maerz; Pantelis Poumbourios
Journal:  FEBS Lett       Date:  2003-07-10       Impact factor: 4.124

4.  Thermal stability and inactivation of hepatitis C virus grown in cell culture.

Authors:  Hongshuo Song; Jin Li; Shuang Shi; Ling Yan; Hui Zhuang; Kui Li
Journal:  Virol J       Date:  2010-02-18       Impact factor: 4.099

5.  Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry.

Authors:  Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

6.  Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes.

Authors:  M Hijikata; Y K Shimizu; H Kato; A Iwamoto; J W Shih; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

7.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

Review 9.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

10.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

View more
  14 in total

1.  Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing.

Authors:  Brendan A Palmer; Zoya Dimitrova; Pavel Skums; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

2.  Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.

Authors:  Jannick Prentoe; Stéphanie B N Serre; Santseharay Ramirez; Alfredo Nicosia; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

3.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

4.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

5.  Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment.

Authors:  Eike Steinmann; Juliane Doerrbecker; Martina Friesland; Nina Riebesehl; Corinne Ginkel; Julia Hillung; Juliane Gentzsch; Chris Lauber; Richard Brown; Anne Frentzen; Thomas Pietschmann
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

6.  Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.

Authors:  Christian K Mathiesen; Jannick Prentoe; Luke W Meredith; Tanja B Jensen; Henrik Krarup; Jane A McKeating; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 7.  Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design.

Authors:  Alexander W Tarr; Tanvi Khera; Kathrin Hueging; Julie Sheldon; Eike Steinmann; Thomas Pietschmann; Richard J P Brown
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

Review 8.  Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion.

Authors:  Gabrielle Vieyres; Jean Dubuisson; Thomas Pietschmann
Journal:  Viruses       Date:  2014-03-11       Impact factor: 5.048

9.  Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.

Authors:  Reem R Al Olaby; Laurence Cocquerel; Adam Zemla; Laure Saas; Jean Dubuisson; Jost Vielmetter; Joseph Marcotrigiano; Abdul Ghafoor Khan; Felipe Vences Catalan; Alexander L Perryman; Joel S Freundlich; Stefano Forli; Shoshana Levy; Rod Balhorn; Hassan M Azzazy
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

10.  Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus.

Authors:  Dmitry Polyakov; Ekaterina Sinitsyna; Natalia Grudinina; Mariia Antipchik; Rodion Sakhabeev; Viktor Korzhikov-Vlakh; Mikhail Shavlovsky; Evgenia Korzhikova-Vlakh; Tatiana Tennikova
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.